FIG.1


6000
5000
4000
3000
2000
1000
0
Tumor Volume (mm3)
0
5
10
15
Days after Treatment

(A)


5000
4000
3000
2000
1000
0
Tumor Volume (mm3)
Mock + PBS
Mock + IL-18
G47Δ + PBS
G47Δ + IL-18
0
5
10
15
20
Days after Treatment

(B)

BEST AVAILABLE COPY

FIG.2



FIG.3


Left (InoculatedTumors)
Mock + PBS
Mock + IL-18
G47 Δ + PBS
G47 Δ + IL-18
Tumor Volume (mm3)
Days after Treatment
(A)
Right (Non-Inoculated Tumors)
Mock + PBS
Mock + IL-18
G47 Δ + PBS
G47 Δ + IL-18
Tumor Volume (mm3)
Days after Treatment
(B)

FIG.4


Mock + PBS
Mock + IL-18
G47 Δ + PBS
G47 Δ + IL-18
Tumor Volume (mm3)
3500
3000
2500
2000
1500
1000
500
0
0
2
4
6
8
10
Days after Treatment

FIG.5


G47ΔTiter (pfu/tumor)
10^6
10^5
10^4
10^3
10^2
10^1
1
PBS
IL-18
0
2
4
6
8
10
12
Days after Infection

FIG.6


CD4+ T Cell Depletion
Mock + PBS (rat IgG)
G47² + PBS (rat IgG)
G47² + IL-18 (rat IgG)
G47² + PBS (anti-CD4)
G47² + IL-18 (anti-CD4)
3500
3000
2500
2000
1500
1000
500
0
0 2 4 6 8 10 12 14 16
Days after Treatment

(A)


CD8+ T Cell Depletion
Mock + PBS (rat IgG)
G47² + PBS (rat IgG)
G47² + IL-18 (rat IgG)
G47² + PBS (anti-CD8)
G47² + IL-18 (anti-CD8)
3000
2500
2000
1500
1000
500
0
0 2 4 6 8 10 12 14 16
Days after Treatment

(B)

FIG.7


100
90
80
70
60
50
40
30
20
10
0
% Survival
0
5
10
15
20
Days after Tumor Implantation
Mock + PBS
Mock + IL-18
G47Δ+ PBS
G47Δ + IL-18

FIG.8


U_L
U_S
TK
N Bs St N
X B St X G
N St Bs N
B Bs EN Nr
ICP6
γ34.5
γ34.5
US11
α47
lacZ
transgene
PCMV
SV40 pA
BGH pA

FIG.9


Left (Inoculated Tumors)
Mock + PBS
Mock + IL-18
T-mfIL12+ PBS
T-mfIL12 + IL-18
4000
3500
3000
2500
2000
1500
1000
500
0
0
3
6
8
10
13
Days after Treatment
Right (Non-Inoculated Tumors)
Mock + PBS
Mock + IL-18
T-mfIL12+ PBS
T-mfIL12 + IL-18
4000
3500
3000
2500
2000
1500
1000
500
0
0
3
6
8
10
13
Days after Treatment